The company was founded in 2000 and listed on the Shenzhen Stock Exchange GEM on August 19, 2011. The company is a biochemical pharmaceutical enterprise integrating R&D, production, sales, import and export trade. In the field of heparin, it is a key high-tech enterprise with a complete heparin industry chain from crude heparin products to low molecular weight heparin injection products, and is one of the leading companies in the domestic heparin series. Since its establishment, the company has mainly developed, produced and sold drugs to treat cardiovascular and cerebrovascular diseases. The main heparin products are: heparin sodium raw materials, enoxaparin sodium raw materials, low molecular weight heparin calcium injections, heparin sodium injections, and nadroparin calcium injections. Corporate honors: Selected by China Shuangchuang as a model enterprise for entrepreneurship and innovation in China, Wanmaishu brand low molecular weight heparin calcium injection was recognized by the Shijiazhuang Municipal People's Government as the top ten industrial brand products in Shijiazhuang City in 2017.
No Data